Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Treatment Choices in Optic Neuritis: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, or Other?
Optical coherence tomography reflects brain atrophy in MS: A four year study.
Effects of dimethyl fumarate on neuroprotection and immunomodulation.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Keystone Symposium: Gut Microbiota Modulation of Host Physiology: The Search for Mechanism
TECFIDERA prescribing information
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.
Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial
American Academy of Neurology: Breakthroughs in Neurology
Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis.
MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model.
Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response.
Spotlight on teriflunomide.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
The neuroendocrine axis in patients with multiple sclerosis.
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
Pages
« first
‹ previous
…
52
53
54
55
56
57
58
59
60
…
next ›
last »